X4 Pharmaceuticals (XFOR) Operating Leases (2019 - 2025)

X4 Pharmaceuticals' Operating Leases history runs 7 years deep, the most recent figure standing at $994000.0 for Q4 2025.

• Quarterly Operating Leases fell 29.5% year-over-year to $994000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $994000.0 (down 29.5% YoY) and the FY2025 annual result came in at $994000.0, down 29.5% from the prior year.
• Operating Leases was $994000.0 for Q4 2025 at X4 Pharmaceuticals, up from $95000.0 in the prior quarter.
• Across five years, Operating Leases topped out at $6.1 million in Q3 2021 and bottomed at $95000.0 in Q3 2025.
• A 5-year average of $3.3 million and a median of $3.4 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases soared 231.29% — and 2025, when it slumped 94.59%.
• X4 Pharmaceuticals' Operating Leases stood at $4.8 million in 2021, then retreated by 24.56% to $3.6 million in 2022, then retreated by 27.5% to $2.6 million in 2023, then plunged by 46.02% to $1.4 million in 2024, then retreated by 29.5% to $994000.0 in 2025.
• Business Quant data shows XFOR's Operating Leases at $994000.0 in Q4 2025, $95000.0 in Q3 2025, and $815000.0 in Q2 2025.